Medical Oncologist
CION Cancer Clinics
Regorafenib, cabozantinib and ramucirumab for liver cancer | CION Cancer Clinics
Regorafenib, cabozantinib and ramucirumab are second-line medicines for advanced hepatocellular carcinoma, used after the first medicine stops working. Each was tested in a different group, so each suits a different person. This page explains who is usually offered which, why your AFP level matters, who should not take any of them, and what to know about getting them in India. At CION Cancer Clinics, a multidisciplinary tumour board weighs your liver function and your scans before recommending any treatment.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed October 2026, next review due October 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- What are regorafenib, cabozantinib and ramucirumab used for?
- How are the three medicines different from each other?
- Which one is likely to suit which person?
- What checks happen before one of these is started?
- What do families often get wrong about these drugs?
- Who should not take regorafenib, cabozantinib or ramucirumab?
- What this page cannot tell you
- Common questions about the second-line drugs
The short answer
What are regorafenib, cabozantinib and ramucirumab used for?
They are three medicines used for advanced hepatocellular carcinoma (HCC) after the first medicine has stopped working. All three were tested in people whose cancer had grown on sorafenib, and each suits a slightly different person. Two are tablets taken at home. Ramucirumab is a drip given in a day-care chair.
Who this page is for
This page is for HCC, the cancer that starts in the liver itself. If the spots in your liver came from bowel, breast or another organ, these drugs are not the usual choice, and our page on primary versus secondary liver cancer explains why. Bile duct cancer is treated differently too.
How they fit with today's first treatments
When these drugs were tested, sorafenib was the usual first medicine. Today most people start on atezolizumab plus bevacizumab instead. So when one of these three is used after immunotherapy, your team is working from reasoning rather than a trial that tested exactly that order. Our page on second-line treatment covers how that bigger choice is made.
This page explains the decision. How each drug works and how to handle its side effects belong with your oncologist.One by one
How are the three medicines different from each other?
They are not interchangeable. Each was tested in a particular group, and that group is who it is usually offered to.
Regorafenib
A tablet closely related to sorafenib. It blocks several signals the tumour uses to grow and to build blood vessels. It was tested only in people who had coped reasonably well with sorafenib, because it shares many of the same side effects.
Usually considered when
- The cancer grew on sorafenib
- Sorafenib side effects were manageable
Cabozantinib
A tablet that blocks a slightly different set of growth signals. It was tested after sorafenib, including in some people who had already had two earlier medicines. It is sometimes chosen when regorafenib does not fit.
Usually considered when
- The cancer grew on an earlier tablet
- Fitness and liver function are still good
Ramucirumab
An antibody given as a drip that blocks one blood-vessel signal. In its trial it helped only people whose AFP, the liver cancer blood marker, was high. With a low AFP it is not usually offered.
A high AFP is the entry ticket for this drug, not a sign that things are worse for you.What all three share
Each needs a liver that is still working well, usually Child-Pugh A. Each can raise blood pressure. None is a substitute for honest talk about goals.
Not sure whether this applies to you?
Ask an oncologistSide by side
Which one is likely to suit which person?
Your situation
The medicine often discussed
Cancer grew on sorafenib, which you tolerated
Regorafenib or cabozantinib
Sorafenib was stopped because of side effects
Cabozantinib, or ramucirumab if AFP is high; regorafenib is less likely
AFP is high and you prefer to avoid daily tablets
Ramucirumab, given as a drip
First treatment was atezolizumab plus bevacizumab
Usually lenvatinib or sorafenib first; these three may come later
Liver function has worsened to Child-Pugh B or C
Often none of them; comfort-focused care is discussed
Before the first dose
What checks happen before one of these is started?
A fresh scan and blood tests
The team confirms the cancer has really grown and checks bilirubin, albumin, INR and AFP. These decide whether any of the three is safe and which one fits.
Blood pressure and urine checks
All three can push blood pressure up, and ramucirumab can leak protein into the urine. Both are measured at the start so changes can be spotted.
A look at bleeding risk
Drugs that act on blood vessels can make bleeding more likely. If you have large varices, the swollen veins in the food pipe, they may need treating first. Our page on why endoscopy comes first explains this.
A clear talk about availability and cost
Your team checks what can actually be obtained, what it is likely to cost and whether any support programme applies.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Commonly believed
What do families often get wrong about these drugs?
"The newest or costliest drug must be the strongest."
None of the three has been shown to beat the others head to head. The right one is the one that fits your liver, your AFP, your earlier treatment and your side effects, not the one with the highest price.
"If sorafenib failed, a drug like it cannot work."
Regorafenib is related to sorafenib but blocks more signals, and it was tested precisely in people whose cancer grew on sorafenib. Being related does not mean it will fail in the same way.
"Cutting the dose means the treatment has stopped working."
Lowering a dose to control side effects is common with these tablets. It often lets people stay on treatment longer, which matters more than taking the full amount for a short time.
"A herbal liver tonic will protect the liver during treatment."
Some herbal products can damage a liver that is already under strain, and some interact with these drugs. Tell your oncologist everything you take. You will not be judged for it.
Not for everyone
Who should not take regorafenib, cabozantinib or ramucirumab?
These drugs do not work for everyone, and for some people they cause more harm than help. If the liver is struggling, with jaundice, fluid in the abdomen that keeps returning or episodes of confusion, the liver itself usually becomes the bigger danger. Our page on systemic treatment with Child-Pugh B covers that grey zone.
Other reasons the team may advise against
Recent bleeding, untreated large varices, a recent heart attack or stroke, uncontrolled blood pressure, a wound that has not healed or planned surgery can all rule out one or more of the three. Someone who now spends most of the day in bed tends to feel the side effects more than any benefit.
On availability in India
Regorafenib and cabozantinib can usually be obtained in India, and cheaper generic versions exist for some. Ramucirumab can be harder to source, and supply changes. Your oncologist will check before suggesting it, and our page on drug access and assistance programmes explains what help exists.
Being straight with you
What this page cannot tell you
It cannot tell you which of the three is right for you, or whether any of them is. That depends on your scans, your blood results, the medicines you have had and how your body handled them. A medical oncologist who has seen all of it is the person to decide with you.
It cannot predict how long a drug will work
Trials report averages across many people. Some people do much better than the average and some do worse. Nobody can promise a length of time, and you should be wary of anyone who does.
The evidence after immunotherapy is thin
All three were tested after sorafenib. Most people now start on immunotherapy, so their use afterwards rests on judgement. CION offers second opinions if you want another team to look at the plan.
Questions we are asked
Common questions about the second-line drugs
Which is better, regorafenib or cabozantinib?
They have never been compared directly in a trial, so neither can be called better overall. Regorafenib is usually kept for people who coped with sorafenib. Cabozantinib is an option for a wider group. Your oncologist chooses based on your history and side effects.
Why will my doctor not give me ramucirumab?
Most often because your AFP is not high enough. In its trial, ramucirumab helped only people with a high AFP. Giving it with a low AFP would mean the side effects and the cost without good evidence of benefit.
What are the main side effects?
The two tablets commonly cause sore, peeling skin on the hands and feet, raised blood pressure, loose stools and tiredness. Ramucirumab more often raises blood pressure, causes swelling in the legs and leaks protein into the urine. Our page on the hand-foot reaction explains that problem.
Can these drugs be taken with hepatitis B?
Yes, as long as the hepatitis B is controlled. If you take antiviral tablets, keep taking them throughout. Your liver specialist or physician manages the antiviral, and your oncologist needs to know you are on it.
Where is treatment given?
The tablets are taken at home, with regular visits to check blood pressure, blood tests and side effects at a CION centre. Ramucirumab is given as a drip in the day-care unit. Families travelling from districts can usually plan visits around this.
How will we know if the drug is working?
Through repeat scans and blood tests at intervals your team sets, and through how you feel. Our page on how response is assessed explains what the team looks for on the scan.
What happens if the second drug also stops working?
Some people can try a further medicine, and some may be suitable for a clinical trial. For others, the kinder path is care focused on comfort. Our page on third-line and beyond covers this honestly.
Can Aarogyasri or insurance cover these drugs?
Sometimes, but scheme and policy rules on cancer tablets and infusions change and differ from plan to plan. Check what your scheme or insurer covers at the time you start. The CION team can help with the paperwork.
Your Specialists
Meet CION's liver cancer specialists. Bring your scan reports and liver blood tests.
Our medical and surgical oncologists plan liver cancer care together, weighing the tumour and how well your liver works before choosing surgery, a liver-directed procedure or medicines.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- American Cancer Society — Targeted Drug Therapy for Liver Cancer
- National Cancer Institute — Liver Cancer Treatment
- EASL — EASL Clinical Practice Guidelines: management of hepatocellular carcinoma
- MedlinePlus — Alpha Fetoprotein (AFP) Tumor Marker Test
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Second-Line Treatment After First-Line FailsHow the bigger choice of what comes next is madeThird-Line and BeyondIf the second medicine also stops workingPatient Assistance and Drug Access ProgrammesHelp with getting and paying for these medicinesWhen Sorafenib Stops Working: What Comes NextThe sorafenib side of the same decision
Talk to us
Wondering which second-line medicine fits?
Share your latest scan, blood reports and treatment history, and a medical oncologist will explain which options are realistic for you. One helpline serves every CION centre.